Project Grant R21OD037651

Award Date 7/1/24
Completion Date 6/30/26
Dollars Obligated $236K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
Kingston, RI 02881, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) supports the development of innovative in vivo animal models for studying mitochondrial DNA (mtDNA) diseases. The $629,508 award to the University of Texas at Austin, effective September 16, 2024 through August 31, 2028, aims to generate designer zebrafish models with specific mtDNA variants to enable new research approaches for diagnosing and treating these complex...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $146,922 to the University of Southern California to conduct research aimed at triggering the selective removal of deleterious mitochondrial DNA (mtDNA) mutations from mammalian cells. The goal is to develop treatments to prevent or ameliorate age-related and pediatric diseases associated with mtDNA mutations. The research will utilize genetic and molecular biology tools, combined with...
This Project Grant award of $198,750.00 from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) will be used by the University of Texas at Austin to develop conditional animal models for studying mitochondrial diseases. The goal is to establish a toolkit to enable precise CRISPR-based editing of the mitochondrial genome, which will facilitate the study of different pathogenic mitochondrial DNA variations and provide insights into the underlying mechanisms of...
This Project Grant award, with Federal Grant ID R00HD109359, was provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The $498,000 grant aims to develop the first murine animal model and adeno-associated virus (AAV)-based gene therapy for mtatp6 mitochondrial diseases, which currently lack approved treatments. The key products and services to be delivered include: Developing and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $793,777 to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA, to study the impact of mitochondrial genome architecture on the accumulation of somatic mitochondrial DNA (mtDNA) mutations over an individual's lifetime. The research aims to understand how mtDNA compaction influences mutation rates and mitochondrial health, with potential...
This Project Grant award of $1,156,508 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of mitochondrial metabolism in regulating species-specific developmental rates. The project aims to leverage an in vitro system that recapitulates the difference in developmental rate between mouse and human cells to understand why basal metabolic rates are elevated in mouse...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $1,555,000 to the University of Washington to conduct research focused on understanding the regulation of mitochondrial DNA (mtDNA) heteroplasmy and integrity. The key objectives of this 5-year project are to: 1) Use single-cell and ultra-high accuracy sequencing methods to assess how mitochondrial quality control...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) federal grant program, provides $622,000 to the University of Maryland, Baltimore to investigate the role of mitochondrial complex I deficiency in Alzheimer's disease (AD) and dementia. The key objectives are to: 1) Determine the effects of complex I deficiency on humanized amyloid-beta (Aβ) proteinopathy, a hallmark of AD, and 2) Assess the susceptibility of complex I-deficient mice to AD...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a comprehensive investigation into the relationship between mitochondrial function and aging-related diseases. The $2,672,656 award to The Johns Hopkins University will leverage genetic variation data, metabolomics, and proteomics to identify novel biomarkers of mitochondrial function and assess their causal associations with all-cause mortality, cardiovascular disease, and frailty. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $399,766 to the University of Kansas Center for Research Inc. from January 1, 2025 to December 31, 2026. The project aims to understand the dynamics between mitochondrial and nuclear genome variation, and how this impacts mitochondrial dysfunction and associated diseases like neuromuscular disorders, cancers, and metabolic diseases. The research will leverage a novel animal model, the threespine...

NOVEL KNOCK-IN MTDNA MOUSE MODEL TO STUDY MITOCHONDRIAL DYSFUNCTION - PROJECT SUMMARY / ABSTRACT MITOCHONDRIAL DYSFUNCTION (MD) PLAYS A CENTRAL ROLE IN THE PATHOPHYSIOLOGY OF MANY HUMAN DISEASES COMMONLY REFERRED AS NON-COMMUNICABLE DISEASES (NCDS). NCDS ARE NON-INFECTIOUS, NON-TRANSMISSIBLE DISORDERS CHARACTERIZED BY LOW-GRADE CHRONIC INFLAMMATION, AMONG WHICH THE MOST COMMON ARE OBESITY, INSULIN RESISTANCE, DIABETES, FORMS OF CANCER, CARDIOVASCULAR DISEASES, AND NONALCOHOLIC FATTY LIVER DISEASE. NCDS AFFECT AN ESTIMATED 41 MILLION PEOPLE EACH YEAR. ADDITIONALLY, MD HAS ALSO BEEN IMPLICATED IN AGING AND AGE-RELATED DISEASES, INCLUDING NEUROLOGICAL DISORDERS SUCH AS ALZHEIMER'S DISEASE AND RELATED DEMENTIAS, WHICH REPRESENT THE SIXTH-LEADING CAUSE OF DEATH IN THE UNITED STATES, WITH COST FOR LONG-TERM AND HOSPICE CARE CALCULATED TO BE AROUND 200 BILLION DOLLARS PER YEAR. ONE CAUSE OF MD IS AN INCREASE IN MITOCHONDRIAL DNA (MTDNA) MUTATIONS RESULTING IN IMPAIRED OXIDATIVE PHOSPHORYLATION THAT LEADS TO LOSS OF BIOENERGETIC HOMEOSTASIS, INCREASED CELL APOPTOSIS, AND SENESCENCE. TO ADDRESS THE ROLE OF MTDNA MUTATIONS ON TISSUE/ORGAN HOMEOSTASIS, TWO INDEPENDENT GROUPS DEVELOPED A KNOCK-IN MOUSE EXPRESSING A PROOFREADING-DEFICIENT VERSION OF THE NUCLEUS- ENCODED CATALYTIC SUBUNIT OF MTDNA POLYMERASE-G (POLGA). THE MTDNA MUTATOR MOUSE MODEL DEMONSTRATES A CAUSE-AND-EFFECT RELATIONSHIP BETWEEN SLOWLY INCREASING SOMATIC MTDNA MUTATION LEVELS AND SEVERAL PHENOTYPES ASSOCIATED WITH AGING THAT MANIFEST MUCH EARLIER IN LIFE, INCLUDING REDUCED LIFESPAN, WEIGHT LOSS, ALOPECIA, ANEMIA, KYPHOSIS, OSTEOPOROSIS, SARCOPENIA, AND LOSS OF SUBCUTANEOUS FAT. ALTHOUGH THIS MOUSE MODEL HAS BEEN KEY TO UNDERSTAND THE EFFECT OF MTDNA MUTATIONS DRIVEN MD ON ORGANISMAL HEALTH, THE GLOBAL MD RESULTS IN OVERALL TISSUE/ORGAN DYSFUNCTION AND MAKES IT DIFFICULT TO DISSECT HOW DIFFERENT TISSUES ARE AFFECTED AND COMPENSATE FOR MD, SINCE IT HAS NOT POSSIBLE TO SEPARATE SINGLE ORGAN DYSFUNCTION FROM OTHER ORGANS EQUALLY AFFECTED BY MD. MOREOVER, DUE TO THE OVERALL MARKED AND SEVERE PROGEROID PHENOTYPES THAT AFFECT THE AUDITORY, VISUAL, AND AMBULATORY SYSTEMS IN THIS MODEL, IT HAS NOT BEEN POSSIBLE TO TEST HOW MD AFFECTS BRAIN HEALTH AND COGNITION. TO OVERCOME THIS LIMITATION, WE HAVE GENERATED A NOVEL KNOCK-IN INDUCIBLE MTDNA MUTATOR MOUSE (RJA- POLGACDS/CDS) WITH BOTH SPATIAL AND TEMPORAL REGULATION CAPABILITIES THAT WILL ALLOW US TO STUDY THE EFFECT OF MTDNA MUTATION-INDUCED MD IN SINGLE TISSUES AT DIFFERENT TIME-POINTS. THE OVERALL GOAL OF THIS PROPOSAL IS TO VALIDATE THIS NEW MOUSE MODEL AND DEMONSTRATE ITS UTILITY IN STUDYING THE ROLE OF MD IN A BROAD RANGE OF HUMAN DISEASES. WE WILL TEST ITS TEMPORAL AND SPATIAL INDUCIBILITY BY CROSSING IT WITH A WHOLE-BODY EXPRESSING CRE MOUSE (AIM 1) AS WELL AS INDUCIBLE (CREERT2) AND MUSCLE-SPECIFIC (ACTA1-CRE) CRE-EXPRESSING MOUSE LINES (AIM 2). THE PROPOSED WORK IS HIGHLY RESPONSIVE IN ADDRESSING IMPORTANT KNOWLEDGE GAPS IN UNDERSTANDING THE ROLE OF MD ON ORGAN HOMEOSTASIS, INCLUDING ITS ROLE ON ONSET AND PROGRESSION OF MANY HUMAN DISEASES. SUCCESSFUL COMPLETION OF THIS WORK WILL PROVIDE A NOVEL AND UNIQUE ANIMAL MODEL TO INVESTIGATE THE RELATIONSHIP BETWEEN MD AND SEVERAL DISEASES AND WILL PROVIDE A NOVEL PLATFORM TO INVESTIGATE THERAPEUTIC STRATEGIES TO TARGET THESE PATHOLOGIES.

Posted 6/25/24, 12:00 AM